Mutational analysis of the affinity maturation of antibody 48G7.

The affinity maturation of antibody 48G7 from its germline predecessor 48G7g has been studied at a molecular level through a combination of structural and biochemical means. Each of the nine somatic mutations accumulated during affinity maturation has been assessed for gain or loss of function in both the germline and affinity-matured antibodies. Individual somatic mutations were found to be either positive or neutral in their effects on affinity for hapten JWJ1, with a marked context-dependence for some sites of mutation. In a number of cases significant cooperativity was found between pairs of somatically mutated residues. Interpretation of the structural changes introduced by many of the point mutations has been possible due to the availability of high-resolution crystal structures of 48G7g and 48G7, and mechanisms by which these structural changes may result in enhanced affinity for hapten have been identified. Precise dissection of structure-function relationships in this system provides additional insights into the role of cooperativity in the evolution of antibody affinity. Comparison of 48G7 with previously characterized systems provides a varied view of the structure-function mechanisms by which the humoral immune system produces large increases in affinity.

[1]  J. Zhang,et al.  Correlation between the substitution rate and rate variation among sites in protein evolution. , 1998, Genetics.

[2]  P. Schultz,et al.  Immunological origins of binding and catalysis in a Diels-Alderase antibody. , 1998, Science.

[3]  N. Green,et al.  Somatic hypermutation of antibody genes: a hot spot warms up , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[4]  P. Schultz,et al.  Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies. , 1998, Journal of molecular biology.

[5]  Peter G. Schultz,et al.  The interplay between binding energy and catalysis in the evolution of a catalytic antibody , 1997, Nature.

[6]  R C Stevens,et al.  Structural insights into the evolution of an antibody combining site. , 1997, Science.

[7]  P. Schultz,et al.  Crystal structures of the free and liganded form of an esterolytic catalytic antibody. , 1997, Journal of molecular biology.

[8]  Y. Pewzner‐Jung,et al.  Structural elements controlling anti-DNA antibody affinity and their relationship to anti-phosphorylcholine activity. , 1996, Journal of immunology.

[9]  Peter G. Schultz,et al.  The Immunological Evolution of Catalysis , 1996, Science.

[10]  T. Manser,et al.  Evaluation of loss and change of specificity resulting from random mutagenesis of an antibody VH region. , 1995, Journal of immunology.

[11]  P. Schultz,et al.  Expression studies of catalytic antibodies. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Y. Satow,et al.  Three-dimensional structures of the Fab fragment of murine N1G9 antibody from the primary immune response and of its complex with (4-hydroxy-3-nitrophenyl)acetate. , 1995, Journal of molecular biology.

[13]  N. Maizels,et al.  Somatic hypermutation: How many mechanisms diversify V region sequences? , 1995, Cell.

[14]  L. Amzel,et al.  Structural analysis of affinity maturation: the three-dimensional structures of complexes of an anti-nitrophenol antibody. , 1995, Molecular immunology.

[15]  R. Lerner,et al.  From molecular diversity to catalysis: lessons from the immune system. , 1995, Science.

[16]  A. Sarai,et al.  The Affinity Maturation of Anti-4-hydroxy-3-nitrophenylacetyl Mouse Monoclonal Antibody , 1995, The Journal of Biological Chemistry.

[17]  T. Manser,et al.  Random mutagenesis of two complementarity determining region amino acids yields an unexpectedly high frequency of antibodies with increased affinity for both cognate antigen and autoantigen , 1995, The Journal of experimental medicine.

[18]  V. Roberts,et al.  Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations. , 1995, The EMBO journal.

[19]  P. Kussie,et al.  Modulation of antibody affinity by an engineered amino acid substitution. , 1995, Journal of immunology.

[20]  I. Shimada,et al.  A multinuclear NMR study of the affinity maturation of anti-NP mouse monoclonal antibodies: comparison of antibody combining sites of primary response antibody N1G9 and secondary response antibody 3B62. , 1993, Biochemistry.

[21]  C. Milstein,et al.  Affinity maturation leads to differential expression of multiple copies of a κ light-chain transgene , 1993, Nature.

[22]  G. Petsko,et al.  Three-dimensional structure of murine anti-p-azophenylarsonate Fab 36-71. 1. X-ray crystallography, site-directed mutagenesis, and modeling of the complex with hapten. , 1991, Biochemistry.

[23]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[24]  K. Mori,et al.  Immunoglobulin superfamily molecules in the nervous system , 1991, Neuroscience Research.

[25]  L. Wysocki,et al.  Clustered H chain somatic mutations shared by anti-p-azophenylarsonate antibodies confer enhanced affinity and ablate the cross-reactive idiotype. , 1990, Journal of immunology.

[26]  J. Sharon.  Structural correlates of high antibody affinity: three engineered amino acid substitutions can increase the affinity of an anti-p-azophenylarsonate antibody 200-fold. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Wysocki,et al.  Single germline VH and V kappa genes encode predominating antibody variable regions elicited in strain A mice by immunization with p- azophenylarsonate , 1987, The Journal of experimental medicine.

[28]  C. Milstein,et al.  Light chain germ‐line genes and the immune response to 2‐phenyloxazolone. , 1985, The EMBO journal.

[29]  G. M. Griffiths,et al.  Molecular events during maturation of the immune response to oxazolone , 1985, Nature.

[30]  C. Milstein,et al.  Somatic mutation and the maturation of immune response to 2-phenyl oxazolone , 1984, Nature.

[31]  M. Kimura,et al.  The length of time required for a selectively neutral mutant to reach fixation through random frequency drift in a finite population. , 1970, Genetical research.

[32]  R. Korngold,et al.  Immunoglobulin superfamily proteins: structure, mechanisms, and drug discovery. , 1997, Biopolymers.

[33]  M. Neuberger,et al.  Somatic hypermutation of immunoglobulin genes. , 1996, Annual review of immunology.

[34]  C. Milstein,et al.  Three‐dimensional structure determination of an anti‐2‐phenyloxazolone antibody: the role of somatic mutation and heavy/light chain pairing in the maturation of an immune response. , 1990, The EMBO journal.

[35]  D. Allen,et al.  Modulation of antibody binding affinity by somatic mutation , 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[36]  C. Milstein,et al.  Preliminary crystallographic study of the Fab fragments of two monoclonal anti-2-phenyloxazolone antibodies. , 1985, The Journal of biological chemistry.

[37]  Thomas A. Kunkel,et al.  Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.